RxDoctor Payments Data

Jessica Goergen

Family · Smyrna, GANPI 1871085530

Payments from drug & device makers

$705in general payments, 2019–2025

Across 28 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$167
  • Sumitomo Pharma America, Inc.$115
  • 180 Medical, Inc.$79
  • Urogen Pharma, Inc.$64
  • AstraZeneca$57
  • Bayer$42
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$67095%
  • Education$355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$705 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$48,773
Medicare patients
348
Services billed
2,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron57$58,735
GemtesaVibegron38$28,874
Tamsulosin Hcl335$4,914
Estradiol36$2,381
Tolterodine Tartrate ErTolterodine Tartrate27$2,333
Silodosin13$1,472
Methenamine Hippurate19$1,335
Oxybutynin Chloride ErOxybutynin Chloride55$1,274
Finasteride100$1,267
Alfuzosin Hcl ErAlfuzosin Hcl53$1,220
Solifenacin Succinate22$1,033
Potassium Citrate ErPotassium Citrate11$750
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$652
Oxybutynin Chloride27$616
Desmopressin Acetate13$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$14$58,73557 claims
Sumitomo Pharma America, Inc.Gemtesa$115$28,87438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,258 family providers in Georgia.

Other family in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →